Adagene Reports Strong Muzastotug Phase 1b/2 Data & Announces Incyte Collaboration for MSS CRC

summarizeSummary

Adagene announced updated positive Phase 1b/2 clinical data for muzastotug in MSS CRC, showing dose-dependent efficacy and favorable safety, alongside a new clinical collaboration with Incyte to evaluate muzastotug in combination with INCA33890.

check_boxKey Events

• Updated Phase 1b/2 Clinical Data

  Adagene reported updated positive efficacy and safety results for muzastotug in combination with pembrolizumab in late-line MSS CRC patients. The 20 mg/kg dose cohorts achieved a 31% confirmed overall response rate (ORR), with median progression-free survival (PFS) of 6.7 months and 1-year overall survival (OS) rate of 80.8%.

• Favorable Safety Profile

  The Phase 1b/2 study demonstrated a low 4% overall discontinuation rate, no dose-limiting toxicities, and no Grade 4 or 5 treatment-related adverse events (TRAEs) across all cohorts, highlighting an expanded therapeutic window for CTLA-4 therapy.

• FDA Fast Track Designation

  Muzastotug in combination with pembrolizumab has been designated as a Fast Track product by the FDA for adult patients with MSS metastatic colorectal cancer without current or active liver metastases.

• New Clinical Collaboration with Incyte

  Adagene announced a clinical collaboration with Incyte to evaluate muzastotug in combination with Incyte's TGFβR2xPD-1 bispecific antibody (INCA33890) in MSS CRC patients. Incyte will sponsor and conduct the Phase 1 study, with Adagene providing clinical supply.

auto_awesomeAnalysis

This 6-K filing delivers highly positive news for Adagene, a clinical-stage biotech. The updated Phase 1b/2 data for muzastotug in combination with pembrolizumab demonstrates significant dose-dependent efficacy (31% ORR at 20 mg/kg) and favorable durability and overall survival in late-line microsatellite stable colorectal cancer (MSS CRC), a notoriously difficult-to-treat indication. The robust safety profile, with low discontinuation rates and no Grade 4/5 treatment-related adverse events, is a key differentiator for a CTLA-4 therapy. This strong clinical validation for their lead asset is further bolstered by the new clinical collaboration with Incyte, a major pharmaceutical company, to evaluate muzastotug in a new combination. This partnership provides external validation for Adagene's SAFEbody platform and expands the development pipeline without significant R&D cost to Adagene, as Incyte will sponsor and conduct the study. The FDA Fast Track designation further accelerates the development path towards a potential registrational study. These combined events significantly de-risk Adagene's lead program and enhance its long-term value proposition.